Myocet Plus Endoxan for Older Patients With Breast Cancer
Status:
Terminated
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety and effect on quality of life of
liposomal-encapsulated doxorubicin in combination with cyclophosphamide as first or second
line treatment of older patients (≥ 70 years old) with metastatic breast cancer. The efficacy
of the combination will be correlated with the functional status of patients according to the
comprehensive geriatric assessment